Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Der Nervenarzt
Erschienen in: Der Nervenarzt 5/2010

01.05.2010 | Übersichten

Behandlung kognitiver Defizite bei Schizophrenie

Teil II: Pharmakologische Strategien

verfasst von: Dr. D. Roesch-Ely, U. Pfueller, C. Mundt, U. Müller, M. Weisbrod

Erschienen in: Der Nervenarzt | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

Kognitive Defizite bilden eine klinisch relevante und für den Verlauf entscheidende Symptomgruppe der Schizophrenie. Die pharmakologische Behandlung der kognitiven Defizite stellt eine Herausforderung dar. Ziel dieses Artikels ist es, eine theoretisch fundierte und klinisch bedeutungsvolle Übersicht über die pharmakologischen Strategien der Behandlung kognitiver Defizite bei schizophrenen Psychosen zu geben. Die für die Behandlung schizophrener Psychosen zugelassenen Antipsychotika der 1. Generation sind hinsichtlich ihrer Wirkung auf die Kognition noch kontrovers. Die Antipsychotika der 2. Generation zeigen einen allenfalls geringen positiven Einfluss und sind denen der 1. Generation nicht nachweisbar überlegen. Vielversprechend erscheint der gezielte Einsatz von Präparaten, die kognitive Prozesse spezifisch beeinflussen können, so genannte kognitionsverbessernde Substanzen („cognition-enhancing drugs“).
Literatur
1.
Allain H, Lieury A, Brunet-Bourgin F et al (1992) Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology 106 [Suppl]:56–61
2.
Apud JA, Mattay V, Chen J et al (2007) Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 32:1011–1020CrossRefPubMed
3.
Apud JA, Weinberger DR (2007) Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. CNS Drugs 21:535–557CrossRefPubMed
4.
Arnsten AF, Cai JX, Murphy BL et al (1994) Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 116:143–151CrossRefPubMed
5.
Arnsten AF, Goldman-Rakic PS (1985) Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 230:1273–1276CrossRefPubMed
6.
Arnsten AF, Jentsch JD (1997) The alpha-1 adrenergic agonist, cirazoline, impairs spatial working memory performance in aged monkeys. Pharmacol Biochem Behav 58:55–59CrossRefPubMed
7.
Barch DM, Carter CS (2005) Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 77:43–58CrossRefPubMed
8.
Barnett JH, Croudace TJ, Jaycock S et al (2007) Improvement and decline of cognitive function in schizophrenia over one year: a longitudinal investigation using latent growth modelling. BMC Psychiatry 7:16CrossRefPubMed
9.
Blyler CR, Gold JM (2000) Cognitive Effects of typical antipsychotic treatment: another look. In: Sharma T, Harvey PD (eds) Cognition in Schizophrenia: Impairments, Importance and Treatment Strategies. Oxford Univ Press, Oxford
10.
Bucci L (1987) The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology 91:104–108CrossRefPubMed
11.
Buchanan RW, Conley RR, Dickinson D et al (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165:82–89CrossRefPubMed
12.
Carpenter WT, Gold JM (2002) Another view of therapy for cognition in schizophrenia. Biol Psychiatry 51:969–971CrossRefPubMed
13.
Chamberlain SR, Muller U, Blackwell AD et al (2006) Noradrenergic modulation of working memory and emotional memory in humans. Psychopharmacology 188:397–407CrossRefPubMed
14.
Cooper NJ, Keage H, Hermens D et al (2005) The dose-dependent effect of methylphenidate on performance, cognition and psychophysiology. J Integr Neurosci 4:123–144CrossRefPubMed
15.
Coyle JT, Tsai G (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology 174:32–38CrossRefPubMed
16.
Daniel E, Weinberger D, Goldberg T et al (1991) Effect of amphetamine on regional blood flow during cognitive activation in schizophrenia. J Neurosci 11:1907–1917PubMed
17.
Davidson M, Galderisi S, Weiser M et al (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166:675–682CrossRefPubMed
18.
Davidson M, Harvey P, Bergamn R (1990) Effects of the D1 agonist SKF-39393 combined with haloperidol in schizophrenic patients (letter). Arch Gen Psychiatry 47:190–191PubMed
19.
Delle Chiaie R, Salviati M, Fiorentini S et al (2007) Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. Exp Clin Psychopharmacol 15:563–568CrossRef
20.
Doruk A, Uzun O, Ozsahin A (2008) A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 23:223–227CrossRefPubMed
21.
Elie D, Poirier M, Chianetta J et al (2009) Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol
22.
Ferreri F, Agbokou C, Gauthier S (2006) Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci 31:369–376PubMed
23.
Fletcher PC, Frith CD, Grasby PM et al (1996) Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. J Neurosci 16:7055–7062PubMed
24.
Freedman R, Olincy A, Buchanan RW et al (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165:1040–1047CrossRefPubMed
25.
Friedman JI (2004) Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology 174:45–53CrossRefPubMed
26.
Friedman JI, Adler DN, Temporini HD et al (2001) Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 25:402–409CrossRefPubMed
27.
Friedman JI, Carpenter D, Lu J et al (2008) A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol 28:59–63CrossRefPubMed
28.
Friedman JI, Ocampo R, Elbaz Z et al (2005) The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia. J Clin Psychopharmacol 25:237–242CrossRefPubMed
29.
Frith CD, Mcginty MA, Gergel I et al (1989) The effects of scopolamine and clonidine upon the performance and learning of a motor skill. Psychopharmacology 98:120–125CrossRefPubMed
30.
Ghoneim MM, Block RI, Ping ST et al (1993) The interactions of midazolam and flumazenil on human memory and cognition. Anesthesiology 79:1183–1192CrossRefPubMed
31.
Goff D C, Cather C, Gottlieb J D et al. (2008) Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study. Schizophr Res 106(2–3):320–327
32.
Goff DC, Tsai G, Levitt J et al (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21–27CrossRefPubMed
33.
Goff DC, Lamberti JS, Leon AC et al (2008) A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 33:465–472CrossRefPubMed
34.
Goldberg TE, Bigelow LB, Weinberger DR et al (1991) Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 148:78–84PubMed
35.
Goldberg TE, Goldman RS, Burdick KE et al (2007) Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64:1115–1122CrossRefPubMed
36.
Goldberg TE, Weinberger DR (1996) Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J Clin Psychiatry 57 [Suppl 9]:62–65
37.
Grasby PM, Frith CD, Paulesu E et al (1995) The effect of the muscarinic antagonist scopolamine on regional cerebral blood flow during the performance of a memory task. Exp Brain Res 104:337–348CrossRefPubMed
38.
Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72:41–51CrossRefPubMed
39.
Green MF, Marder SR, Glynn S M et al (2002) The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 51:972–978CrossRefPubMed
40.
Green MF, Marshall JBD, Wirshing WC et al (1997) Does Risperdone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154:799–803PubMed
41.
Hagger C, Buckley P, Kenny JT et al (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34:702–712CrossRefPubMed
42.
Hall H, Sedvall G, Magnusson O et al (1994) Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245–256PubMed
43.
44.
Hashimoto T, Volk DW, Eggan SM et al (2003) Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 23:6315–6326PubMed
45.
Heresco-Levy U, Javitt DC, Ermilov M et al (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610–617CrossRefPubMed
46.
Hirst WD, Stean TO, Rogers DC et al (2006) SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 553:109–119CrossRefPubMed
47.
Hunter MD, Ganesan V, Wilkinson ID et al (2006) Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry 163:2184–2186CrossRefPubMed
48.
Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, n-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69–108CrossRefPubMed
49.
Jones PB, Barnes TR, Davies L et al (2006) Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1087CrossRefPubMed
50.
Keefe RS, Bilder RM, Davis SM et al (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633–647CrossRefPubMed
51.
Keefe RS, Silva SG, Perkins DO et al (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25:201–222PubMed
52.
Kern RS, Glynn SM, Horan WP et al (2009) Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull 35:347–361CrossRefPubMed
53.
Knoflach F, Mutel V, Jolidon S et al (2001) Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A 98:13402–13407CrossRefPubMed
54.
Koike K, Hashimoto K, Takai N et al (2005) Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res 76:67–72CrossRefPubMed
55.
Krystal JH, Karper LP, Bennett A et al (1998) Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 135:213–229CrossRefPubMed
56.
Krystal JH, Karper LP, Seibyl JP et al (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214PubMed
57.
Lewis DA, Cho RY, Carter CS et al (2008) Subunit-selective modulation of GABA Type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry 165(12):1585–1593CrossRefPubMed
58.
Lucas PB, Pickar D, Kelsoe J et al (1990) Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 28:35–40CrossRefPubMed
59.
Medalia A, Gold J, Merriam A (1988) The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 3:249–271PubMed
60.
Meltzer HY, Mcgurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233–255PubMed
61.
Meltzer HY, Sumiyoshi T (2008) Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res 195:98–102CrossRefPubMed
62.
Menzies L, Ooi C, Kamath S et al (2007) Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry 64:156–167CrossRefPubMed
63.
Minzenberg MJ, Carter CS (2008) Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33:1477–1502CrossRefPubMed
64.
Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55:1013–1022CrossRefPubMed
65.
Morein-Zamir S, Turner DC, Sahakian BJ (2007) A review of the effects of modafinil on cognition in schizophrenia. Schizophr Bull 33:1298–1306CrossRefPubMed
66.
Morgan CJ, Curran HV (2008) Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192:306–307CrossRefPubMed
67.
Müller U, Becker T (2008) Kognition und Rehabilitation. In: Kircher T, Gauggel S (eds) Neuropsychologie der Schizophrenie: Symptome, Kognition, Gehirn. Springer, Heidelberg
68.
Müller U, Mottweiler E, Bublak P (2005) Noradrenergic blockade and numeric working memory in humans. J Psychopharmacol 19:21–28CrossRefPubMed
69.
Müller U, Steffenhagen N, Regenthal R et al (2004) Effects of modafinil on working memory processes in humans. Psychopharmacology 177:161–169CrossRefPubMed
70.
Müller U, Yves D, Pollman S (1998) D1-Versus D2-receptor modulation of visualspatial working memory in humans. J Neurosci 18:2720–2728PubMed
71.
Noorbala AA, Akhondzadeh S, Davari-Ashtiani R et al (1999) Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther 24:369–374CrossRefPubMed
72.
O’Neill MJ, Bleakman D, Zimmerman DM et al (2004) AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord 3:181–194CrossRef
73.
Poyurovsky M, Koren D, Gonopolsky I et al (2003) Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol 13:123–128CrossRefPubMed
74.
Purdon SE, Woodward N, Lindborg SR et al (2003) Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology 169:390–397CrossRefPubMed
75.
Raedler TJ, Jahn H, Arlt J et al (2004) Adjunctive use of reboxetine in schizophrenia. Eur Psychiatry 19:366–369CrossRefPubMed
76.
Rockstroh S, Emre M, Tarral A et al (1996) Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans. Psychopharmacology 124:261–266CrossRefPubMed
77.
Roesch-Ely D, Gohring K, Gruschka P et al (2006) Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia. Pharmacopsychiatry 39:115–116CrossRefPubMed
78.
Roesch-Ely D, Scheffel H, Weiland S et al (2005) Differential dopaminergic modulation of executive control in healthy subjects. Psychopharmacology 178:420–430CrossRefPubMed
79.
Roesch-Ely D, Weiland S, Scheffel H et al (2006) Dopaminergic modulation of semantic priming in healthy volunteers. Biol Psychiatry 60:604–611CrossRefPubMed
80.
Roth BL, Hanizavareh SM, Blum AE (2004) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 174:17–24CrossRefPubMed
81.
Sacco KA, Creeden C, Reutenauer EL et al (2008) Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Schizophr Res
82.
Sawaguchi T, Goldman-Rakic PS (1991) D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251:947–950CrossRefPubMed
83.
Saykin AJ, Gur RC, Gur RE et al (1991) Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 48:618–624PubMed
84.
Sevy S, Rosenthal MH, Alvir J et al (2005) Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 66:839–843CrossRefPubMed
85.
Shekhar A, Potter WZ, Lightfoot J et al (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165:1033–1039CrossRefPubMed
86.
Siepmann M, Muck-Weymann M, Joraschky P et al (2001) The effects of reboxetine on autonomic and cognitive functions in healthy volunteers. Psychopharmacology 157:202–207CrossRefPubMed
87.
Smith RC, Warner-Cohen J, Matute M et al (2006) Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 31:637–643CrossRefPubMed
88.
Spence SA, Green RD, Wilkinson ID et al (2005) Modafinil modulates anterior cingulate function in chronic schizophrenia. Br J Psychiatry 187:55–61CrossRefPubMed
89.
Spring B, Gelenberg AJ, Garvin R et al (1992) Amitriptyline, clovoxamine and cognitive function: a placebo-controlled comparison in depressed outpatients. Psychopharmacology 108:327–332CrossRefPubMed
90.
Strassnig M, Brar JS, Ganguli R (2006) Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. Schizophr Res 86:269–275CrossRefPubMed
91.
Strauss ME, Reynolds KS, Jayaram G et al (1990) Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res 3:127–129CrossRefPubMed
92.
Sumiyoshi T, Matsui M, Nohara S et al (2001) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722–1725CrossRefPubMed
93.
Sumiyoshi T, Park S, Jayathilake K et al (2007) Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 95:158–168CrossRefPubMed
94.
Szeszko PR, Bilder RM, Dunlop JA et al (1999) Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biol Psychiatry 45:680–686CrossRefPubMed
95.
96.
Thiel CM (2003) Cholinergic modulation of learning and memory in the human brain as detected with functional neuroimaging. Neurobiol Learn Mem 80:234–244CrossRefPubMed
97.
Turner DC, Clark L, Pomarol-Clotet E et al (2004) Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29:1363–1373CrossRefPubMed
98.
Turner DC, Robbins TW, Clark L et al (2003) Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 165:260–269PubMed
99.
Voss B, Thienel R, Leucht S et al (2008) Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview. Nervenarzt 79:47–48, 50–42, 54–49CrossRefPubMed
100.
Wagner M, Quednow BB, Westheide J et al (2005) Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 30:381–390CrossRefPubMed
101.
Weickert TW, Goldberg TE, Marenco S et al (2003) Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 28:1491–1500CrossRefPubMed
102.
Wingen M, Kuypers KP, Ramaekers JG (2007) Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI. J Psychopharmacol 21:477–485CrossRefPubMed
103.
Wittorf A, Sickinger S, Wiedemann G et al (2008) Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study. Arch Clin Neuropsychol 23:271–282CrossRefPubMed
104.
Woodward ND, Purdon SE, Meltzer HY et al (2007) A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 89:211–224CrossRefPubMed
105.
Woodward ND, Purdon SE, Meltzer HY et al (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457–472CrossRefPubMed
Metadaten
Titel
Behandlung kognitiver Defizite bei Schizophrenie
Teil II: Pharmakologische Strategien
verfasst von
Dr. D. Roesch-Ely
U. Pfueller
C. Mundt
U. Müller
M. Weisbrod
Publikationsdatum
01.05.2010
Verlag
Springer-Verlag
Erschienen in
Der Nervenarzt / Ausgabe 5/2010
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-009-2919-6

Weitere Artikel der Ausgabe 5/2010

Der Nervenarzt 5/2010 Zur Ausgabe

Mitteilungen der DGPPN

Mitteilungen der DGPPN

Originalien

Psychische Faktoren bei Magenbandimplantation

CME Weiterbildung · Zertifizierte Fortbildung

Diagnostik und Behandlung akuter psychoorganischer Syndrome

Aktuelles

Risikoeinschätzung bei Amokdrohungen

Leserbriefe

Zu Begutachtungsstandards bei posttraumatischer Belastungsstörung

Leitthema

Akut- und Langzeittherapie der bipolaren Depressionen

Neu in den Fachgebieten Neurologie und Psychiatrie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Bildnachweise